A Phase I Dose-Escalation and Safety Study of ZD6474 (ZACTIMA) Used In Combination With Radiation Therapy for Patients With Inoperable/Unresectable Non-Small Cell Lung Cancer.

Trial Profile

A Phase I Dose-Escalation and Safety Study of ZD6474 (ZACTIMA) Used In Combination With Radiation Therapy for Patients With Inoperable/Unresectable Non-Small Cell Lung Cancer.

Withdrawn prior to enrolment
Phase of Trial: Phase I

Latest Information Update: 08 May 2014

At a glance

  • Drugs Vandetanib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 12 Mar 2014 According to ClinicalTrials.gov record, the trial phase changed from I/II to I.
    • 12 Mar 2014 According to ClinicalTrials.gov record, the trial phase changed from I/II to I.
    • 12 Mar 2014 New source identified and integrated (ClinicalTrials.gov; NCT02087839).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top